Skip to nav Skip to content
Mohammed  Al-Jumayli

Mohammed Al-Jumayli, MD

4.8 (137)

Specialty: Medical Oncology

Program: Senior Adult Oncology

  • Overview

    Cancer Focus:
    Adrenal Carcinoma, Colorectal Cancer, Esophageal Cancer, Gallbladder Cancer, Gastrointestinal Carcinoid Tumor, Inflammatory Breast Cancer, Kidney (Renal Cell) Cancer, Liver Cancer, Lung Cancer, Neuroendocrine Tumor, Pancreatic Cancer, Prostate Cancer, Small Intestine Cancer, Stomach (Gastric) Cancer

    Dr. Al-Jumayli is certified in Hematology, Medical Oncology, and Geriatric Medicine. He received his medical degree from Al-Mustansiriyah University College of Medicine, Iraq. He completed an Internal Medicine Residency at Capital Health Regional Medical Center in New Jersey, followed by a Geriatric Fellowship at Baylor College of Medicine, Texas. He completed a Hematology-Oncology Fellowship at the University of Kansas. Dr. Al-Jumayli’s clinical focus is on the treatment of cancer in senior adults, particularly gastrointestinal Oncolgoy (GI) cancer with providing a personalized cancer care based on patients’ functional status, general health, values, and goals. His research focuses on better understanding patients’ ability to tolerate aggressive cancer therapies based on their biologic age and general health through uncovering specific individual characteristics, genetic mutations and biomarkers. 

  • Participating Trials

    Clinical Trial 21227
    A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)
    Condition: Gastrointestinal Tumor
    Status: Open

    Clinical Trial 22153
    Feasibility of Exercise Prehabilitation Among Older Patients with Hepatobiliary Cancer Planning for Surgery
    Condition: Gastrointestinal Tumor
    Status: Open

    If you believe you are eligible for one of these trials or studies, please call
    813-745-6100 or toll-free 1-800-679-0775.

  • Publications

    • Akhtar OS, Cao B, Wang X, Torka P, Al-Jumayli M, Locke FL, Freeman CL. CAR T-Cell Therapy Has Comparable Efficacy to Autologous Transplantation in Older Adults with DLBCL in Partial Response. Blood Adv. 2023 May. Pubmedid: 37236167.
    • Nguyen OT, Lee J, Tabriz AA, Hong YR, Al Jumayli M, Reblin M, Turner K. Evaluation of Employment Loss and Financial Hardship Among US Adults With Disabilities During the COVID-19 Pandemic. JAMA Netw Open. 2023 Mar.6(3):e233364. Pubmedid: 36929405. Pmcid: PMC10020877.
    • Nguyen OT, Turner K, Lee J, Hong YR, Al-Jumayli M, Alishahi Tabriz A. Clinical trial knowledge among U.S. adults aged 65 years and up: Findings from a 2020 national survey. J Am Geriatr Soc. 2023 Jun.71(6):1917-1922. Pubmedid: 36715227.
    • Al-Jumayli M, Kawsar HI, Neupane P. Clinical Outcomes of Different Treatment Modalities in Anaplastic Thyroid Cancer: A Single Center Experience. Am J Ther. 2023 Jan.29(6):e714-e716. Pubmedid: 32889810.
    • Al-Jumayli M, Choucair K, Al-Obaidi A, Park R, Bansal A, Baranda J, Sun W, Saeed A. Pre-operative Carboplatin/Paclitaxel Versus 5-Fluorouracil (5-FU)-based Chemoradiotherapy for Older Adults With Esophageal Cancer. Anticancer Res. 2022 Jan.42(1):59-66. Pubmedid: 34969709.
    • Extermann M, Chetty IJ, Brown SL, Al-Jumayli M, Movsas B. Predictors of Toxicity Among Older Adults with Cancer. Semin Radiat Oncol. 2022 Apr.32(2):179-185. Pubmedid: 35307121.
    • Al-Jumayli M, Brown SL, Chetty IJ, Extermann M, Movsas B. The Biological Process of Aging and the Impact of Ionizing Radiation. Semin Radiat Oncol. 2022 Apr.32(2):172-178. Pubmedid: 35307120.
    • Ripp J, Mohyuddin GR, Al-Jumayli M, Huang C. Outcomes in older patients with NSCLC receiving immunotherapy: A single center experience. Geriatr Oncol. 2021 Sep.12(7):1104-1106. Pubmedid: 33619001.
    • Park R, Al-Jumayli M, Miller K, Saeed A, Saeed A. Exceptional response to Erlotinib monotherapy in EGFR Exon 19-deleted, KRAS wild-type, Chemo-refractory advanced pancreatic adenocarcinoma. Cancer Treat Res Commun. 2021 Feb.27:100342. Pubmedid: 33611092.
    • Kasi A, Al-Jumayli M, Park R, Baranda J, Sun W. Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review. J Pancreat Cancer. 2020 Dec.6(1):107-115. Pubmedid: 33376937. Pmcid: PMC7757687.
    • Saeed A, Hildebrand H, Park R, Al-Jumayli M, Abbasi S, Melancon T, Saeed A, Al-Rajabi R, Kasi A, Baranda J, Williamson S, Sun W. Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study. J Clin Med. 2020 Aug.9(9). Pubmedid: 32824968. Pmcid: PMC7563439.
    • Park R, Eshrat F, Al-Jumayli M, Saeed A, Saeed A. Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma. Vaccines (Basel). 2020 Aug.8(3). Pubmedid: 32784389. Pmcid: PMC7563532.
    • Al-Jumayli M, Batool A, Middiniti A, Saeed A, Sun W, Al-Rajabi R, Baranda J, Kumer S, Schmitt T, Chidharla A, Kasi A. Clinical Outcome of Ampullary Carcinoma: Single Cancer Center Experience. J Oncol. 2019 May.2019:3293509. Pubmedid: 31186632. Pmcid: PMC6521487.
    • Saeed A, Park R, Al-Jumayli M, Al-Rajabi R, Sun W. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma. Clin Colorectal Cancer. 2019 May.18(2):81-90. Pubmedid: 30905548.
    • Park SC, Hsu AT, Su D, Simonson JL, Al-Jumayli M, Liu Y, Liebmann JM, Ritch R. Factors associated with focal lamina cribrosa defects in glaucoma. Invest Ophth Vis Sci. 2013 Dec.54(13):8401-8407. Pubmedid: 24255039.
  • Patient Comments

    Overall Satisfaction


    137 patients rated this provider

    The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

    Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

    Learn more about our patient satisfaction survey



    Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

    We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

    Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

    Learn more about our patient comments

    Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

    • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
    • He or she may be a researcher or other type of provider that does not see patients.
    • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.

    Learn more about our patient satisfaction survey, ratings and comments

Find a Doctor